{"organizations": [], "uuid": "9d76c1fcc9e9251f6dc12f61944e474014ef256c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180201.html", "section_title": "Archive News &amp; Video for Thursday, 01 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-boston-scientific-reports-q4-adjus/brief-boston-scientific-reports-q4-adjusted-earnings-per-share-0-34-idUSASB0C3G0", "country": "US", "domain_rank": 408, "title": "BRIEF-Boston Scientific Reports Q4 Adjusted Earnings Per Share $0.34", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-01T19:36:00.000+02:00", "replies_count": 0, "uuid": "9d76c1fcc9e9251f6dc12f61944e474014ef256c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-boston-scientific-reports-q4-adjus/brief-boston-scientific-reports-q4-adjusted-earnings-per-share-0-34-idUSASB0C3G0", "ord_in_thread": 0, "title": "BRIEF-Boston Scientific Reports Q4 Adjusted Earnings Per Share $0.34", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters) - boston scientific corp", "sentiment": "neutral"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 1 (Reuters) - Boston Scientific Corp:\n* BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2017\n* Q4 GAAP LOSS PER SHARE $0.45 * Q4 SALES $2.408 BILLION VERSUS I/B/E/S VIEW $2.35 BILLION\n* Q4 EARNINGS PER SHARE VIEW $0.34 -- THOMSON REUTERS I/B/E/S\n* SEES FY 2018 GAAP EARNINGS PER SHARE $0.93 TO $0.98 * SEES Q1 2018 GAAP EARNINGS PER SHARE $0.19 TO $0.22 * Q4 ADJUSTED EARNINGS PER SHARE $0.34 * SEES FY 2018 REVENUE $9.65 BILLION TO $9.8 BILLION * SEES Q1 2018 SALES $2.32 BILLION TO $2.35 BILLION * QTRLY INTERVENTIONAL CARDIOLOGY SALES $636 MILLION VERSUS. $585 MILLION LAST YEAR\n* QTRLY CARDIAC RHYTHM MANAGEMENT SALES $488 MILLION VERSUS $473 MILLION LAST YEAR\n* Q4 LOSS PER SHARE OF $0.45 INCLUDES ESTIMATED ONE-TIME NET INCOME TAX CHARGE OF $861 MILLION\n* SEES FY 2018 ADJUSTED EARNINGS PER SHARE $1.35 TO $1.39 * SEES Q1 2018 ADJUSTED EARNINGS PER SHARE $0.30 TO $0.32 * FY2018 EARNINGS PER SHARE VIEW $1.38, REVENUE VIEW $9.61 BILLION -- THOMSON REUTERS I/B/E/S\n* Q1 EARNINGS PER SHARE VIEW $0.31, REVENUE VIEW $2.32 BILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-01T19:36:00.000+02:00", "crawled": "2018-02-02T12:35:49.000+02:00", "highlightTitle": ""}